Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat
Read and act on the official notice on GOV.UK
In plain English, for the pharmacy team
Why is this relevant to community pharmacy
Duvyzat (givinostat) is a medicine for Duchenne muscular dystrophy. The Medicines and Healthcare products Regulatory Agency (MHRA) says there have been reports of deaths outside the UK and has issued interim advice to reduce risk while the review is finished. This matters to pharmacists and the wider pharmacy team because patients may be taking it long term and may ask about monitoring, side effects, or whether to keep taking it.
What to tell patients
Use your professional judgement for each patient.
- A small number of deaths have been reported outside the UK in people with Duchenne muscular dystrophy while taking Duvyzat.
- Continue taking Duvyzat as prescribed and attend all appointments.
- Tell your doctor about any other medicines you are taking, or if they change.
- Speak to your specialist Duchenne’s team if you have any concerns about your treatment.
- Report any suspected side effects on a Yellow Card.
What needs to be done
- Be aware that Duvyzat is subject to additional monitoring and that the MHRA advises extra heart and blood test monitoring while the review is ongoing.
- Pharmacists: if asked about the medicine, check that patients are following the Duchenne Care UK (North Star) monitoring guidance and know to attend their monitoring appointments.
- Pharmacists: remind patients to tell their doctor about any other medicines they are taking or any changes to their medicines, as stated in the notice.
- Pharmacists and the pharmacy team: report all suspected adverse drug reactions for Duvyzat on a Yellow Card.
- Read and act on the official GOV.UK notice.
Pharmshark summary, checked and approved by Chris Dotchin on 6 Nov 2026. It is not the official notice: always read and act on the GOV.UK notice.
How this summary was written
An AI tool drafted it from the MHRA's own notice and nothing else. A second check compared every line with the notice. Pharmshark's clinical lead then read it against the notice, edited it where needed and approved it. If the MHRA changes the notice, this summary is taken down until it has been checked again.
The MHRA's summary
There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and associated evidence, the MHRA has proposed updates to the product information.
MHRA's audience tags: Cardiovascular disease lipidology, Neurology, Paediatrics neonatology, Pharmacy